Valeria Peli
Overview
Explore the profile of Valeria Peli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barilani M, Peli V, Manzini P, Pistoni C, Rusconi F, Pinatel E, et al.
Int J Biol Sci
. 2024 Dec;
20(15):6255-6278.
PMID: 39664576
Extracellular vesicles (EV) have emerged as promising cell-free therapeutics in regenerative medicine. However, translating primary cell line-derived EV to clinical applications requires large-scale manufacturing and several challenges, such as replicative...
2.
Elia N, Prinelli F, Peli V, Conti S, Barilani M, Mei C, et al.
Front Public Health
. 2024 Nov;
12:1491257.
PMID: 39568604
Introduction: Human induced pluripotent stem cells (hiPSCs), derived from reprogrammed adult somatic cells, hold significant promise for disease modelling, personalized medicine, drug discovery, and regenerative therapies. Public awareness and understanding...
3.
Manzini P, Peli V, Rivera-Ordaz A, Budelli S, Barilani M, Lazzari L
Biotechnol Rep (Amst)
. 2022 Feb;
33:e00708.
PMID: 35198419
Human induced pluripotent stem cells (hiPSCs) must be manufactured as advanced therapy medicinal products (ATMPs) for innovative tissue replacement clinical applications. Yet, production of hiPSCs under current Good Manufacturing Practice...
4.
Rivera-Ordaz A, Peli V, Manzini P, Barilani M, Lazzari L
BioDrugs
. 2021 Nov;
35(6):693-714.
PMID: 34727354
Human induced pluripotent stem cells (hiPSCs) are manufactured as advanced therapy medicinal products for tissue replacement applications. With this aim, the feasibility of hiPSC large-scale expansion in existing bioreactor systems...
5.
Barilani M, Cherubini A, Peli V, Polveraccio F, Bollati V, Guffanti F, et al.
EBioMedicine
. 2020 Jun;
57:102848.
PMID: 32574961
Background: Adult skin fibroblasts represent the most common starting cell type used to generate human induced pluripotent stem cells (F-hiPSC) for clinical studies. Yet, a foetal source would offer unique...
6.
Caretti A, Peli V, Colombo M, Zulueta A
Cells
. 2019 Dec;
9(1).
PMID: 31861724
Mesenchymal stem cells (MSCs) are multipotent non-hematopoietic stem cells residing in many tissues, including the lung. MSCs have long been regarded as a promising tool for cell-based therapy because of...
7.
Barilani M, Peli V, Cherubini A, Dossena M, Dolo V, Lazzari L
Cells
. 2019 Dec;
8(12).
PMID: 31783568
The therapeutic potential of mesenchymal stem cell (MSC) extracellular vesicles (EV) is currently under investigation in many pathological contexts. Both adult and perinatal MSC are being considered as sources of...
8.
Zulueta A, Peli V, Cas M, Colombo M, Paroni R, Falleni M, et al.
Int J Biochem Cell Biol
. 2019 Sep;
116:105622.
PMID: 31563560
Ceramide is emerging as one of the players of inflammation in lung diseases. However, data on its inflammatory role in Cystic Fibrosis (CF) as part of the extracellular machinery driven...
9.
Zulueta A, Colombo M, Peli V, Falleni M, Tosi D, Ricciardi M, et al.
Cell Signal
. 2018 Aug;
51:110-118.
PMID: 30076968
Background: Mesenchymal stromal/stem cells (MSCs) are multi-potent non-hematopoietic stem cells, residing in most tissues including the lung. MSCs have been used in therapy of chronic inflammatory lung diseases such as...